EN DE
Watch CervoMed Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CervoMed Inc (CRVO) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of CervoMed Inc stock $0.77, price $1.69, that is 54.4% below the price, quality 28 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CI CervoMed Inc logo Thin data Nov 10, 2026

CervoMed Inc

CRVO · US

Far too expensive (fair value 54% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Insiders bought $3.0M (6M) 
Fair value $0.7700 · Strongly overvalued 
Quality 28/100 
Falling price (downtrend) 
Weak Growth (revenue YoY −58.9 %/yr in USD) 
Negative free cash flow 
Trails peers (1/5) 
Narrow moat 9/100
Thin data 
Estimate
Watch CervoMed Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$45.47 $1.37 Fair Value $0.7700 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.37 – $45.47 · fair‑value band $0.5800 – $0.9600 · the $1.69 price screens above the $0.7700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow CervoMed in your weekly email

Every Wednesday you see whether CervoMed is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.

Show moreShow less

The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.

Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Stock analysis

CervoMed Inc (CRVO) currently trades at $1.69, while our estimate is $0.7700, 54% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.5800 (bear) to $0.9600 (bull), the price of $1.69 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

CervoMed Inc reported revenue of $4.0M in FY2025 versus $0 in FY2021. Reported net income was −$27.0M in FY2025.

Key figures

Market cap $25.4M Micro · EPS (TTM) $−3.21 · Return on equity −132% · Return on assets (EBIT) −138% (5-year average) · Operating margin −334,925% · Free cash flow −$23.4M · Net cash $8.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 83% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −54%, CRVO screens richer than that median.

Fair Value

Bear $0.5800 Fair Value $0.7700 Bull $0.9600
Price $1.69 · Downside -54.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 5
Are margins and returns getting better?
Cashflow 31
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $3.0M, on Jun 11, 2026.

  • BuyJoshua S BogerDirector, 10% owner955,414 shares at $3.14$3.0MJun 11, 2026
  • BuyWilliam Robert ElderCFO, GC & Secretary3,500 shares at $8.36$29,250Nov 18, 2025
  • BuyMatthew WintonChief Commercial and Business5,000 shares at $8.29$41,430Nov 18, 2025
  • BuyJohn J AlamCEO & President, Director, 10% owner21,600 shares at $8.46$182,736Nov 17, 2025
  • BuySylvie GregoireDirector, 10% owner21,600 shares at $8.46$182,736Nov 17, 2025

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−58.9%
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.2% (1998) → −706.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CRVO screens overvalued: fair value 54% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CervoMed Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −54.4% · Bottom 25%
Profitability
Return on assets −115.2% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.39× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs CRVO
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs CRVO
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs CRVO
Genmab A/S GMAB kr 3,448 kr 3,793 +10% vs CRVO
argenx SE ARGX $960.04 $908.40 −5% vs CRVO
CSL Limited CSL A$202.52 A$185.51 −8% vs CRVO
Moderna, Inc MRNA $223.37 $139.99 −37% vs CRVO
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs CRVO
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs CRVO
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs CRVO

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CervoMed Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CervoMed Inc Fair Value". https://www.fairvalue-calculator.com/stock/CRVO

Frequently asked questions

Is CervoMed Inc (CRVO) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.7700 versus a price of $1.69, about 54% lower (overvalued).
What is the fair value of CRVO?
Our estimate for CervoMed Inc is $0.7700 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.69.
What is the quality score of CRVO?
CervoMed Inc has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CervoMed Inc (CRVO)?
Our calculated price target is the estimate of $0.7700 (as of Nov 10, 2026). Cautious scenario $0.5800, optimistic scenario $0.9600. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CervoMed Inc stock forecast for 2026?
Our estimate puts fair value at $0.7700, about 54% lower versus a price of $1.69 (overvalued). Cautious scenario $0.5800, optimistic scenario $0.9600. The calculation is refreshed regularly with new filings.
What is the intrinsic value of CervoMed Inc (CRVO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CervoMed Inc it is $0.7700 per share (as of Nov 10, 2026), against a price of $1.69.
Is CervoMed Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CRVO trades above its calculated fair value: price $1.69, fair value $0.7700, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRVO?
No. The price is what the market pays today ($1.69); the fair value is what the company's own numbers justify ($0.7700). For CervoMed Inc the two are $0.9200 per share apart. That gap is exactly why we show both numbers side by side.
How much is CervoMed Inc worth?
The market values CervoMed Inc at about $25.4M (market capitalisation, as of Nov 10, 2026). Per share that is $1.69; our models calculate a fair value of $0.7700 per share.
What do the bullish and bearish scenarios say about CRVO?
Our models span a range for CervoMed Inc: cautious scenario $0.5800, base $0.7700, optimistic $0.9600 per share (as of Nov 10, 2026, price $1.69). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CervoMed Inc (CRVO)?
Balance-sheet figures for CervoMed Inc (as of Nov 10, 2026): return on equity −131.5%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is CRVO from its 52-week high?
CervoMed Inc trades at $1.69, about 83% below its 52-week high of $9.94 and 23% above the low of $1.37 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7700 is for.
Which stocks are comparable to CervoMed Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CervoMed Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $1.69, calculated fair value $0.7700 (−54%), Quality Score 28/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. CervoMed Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CervoMed Inc (CRVO)?
The closing price on Nov 13, 2026 was $1.69. Our estimate is $0.7700, about 54% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CervoMed Inc right now?
The price sits above even our optimistic bull case ($0.9600). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CervoMed Inc

How large is the market capitalisation of CervoMed Inc (CRVO)?
The market capitalisation of CervoMed Inc is $25.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of CervoMed Inc (CRVO)?
Earnings per share at CervoMed Inc are $−3.21. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CervoMed Inc (CRVO)?
The return on equity (ROE) of CervoMed Inc is −132% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CervoMed Inc (CRVO)?
On an EBIT basis the return on assets of CervoMed Inc is −138% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CervoMed Inc (CRVO)?
The operating margin of CervoMed Inc is −334,925% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does CervoMed Inc (CRVO) generate?
The free cash flow of CervoMed Inc is −$23.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CervoMed Inc (CRVO) hold?
CervoMed Inc holds more cash than debt, $8.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CervoMed Inc in the live analysis

One click puts CervoMed Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.